AveX­is of­fers com­pelling rea­sons for a fast FDA OK for gene ther­a­py to treat spinal mus­cu­lar at­ro­phy in in­fants

For most in­fants suf­fer­ing from spinal mus­cu­lar at­ro­phy type 1, the chances are quite high that they could die or re­quire con­stant res­pi­ra­to­ry as­sis­tance ear­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.